Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial.

By K. Reich, Frank O. Nestle, K. Papp, J. Ortonne, R. Evans, C. Guzzo, Shu Li, L. Dooley, C. Griffiths. The Lancet, 2005

1,034 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Definition of treatment goals for moderate to severe psoriasis: a European consensus (2010, background): “For example, with the tumour necrosis factor a-antagonist infliximab, there is a fast onset of action and an almost maximum therapeutic response by week 10 of treatment [17].”
TNF-α in promotion and progression of cancer (2006, background): “Deregulated local TNF-α production is characteristic of diseases such as rheumatoid arthritis [11] and Crohn’s disease [15] and treatment with TNF-α antagonists is effective in a majority of patients with some evidence of disease modification.”
Circulating Th17, Th22, and Th1 Cells Are Increased in Psoriasis (2009, positive): “Each of these patients received intravenous infusions of infliximab 5 mg kg 1 at weeks 0, 2, 6, 14, and 22, a dose of infliximab previously shown to be highly effective for psoriasis (Reich et al., 2005).”
Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis. (2012, neutral): “Headache 1 (4) 4 (14) 4 (13) 1 (3) 1 (4)”